COVID-19 Vaccine’s Nanoparticle-based mRNA Delivery System Creates Opportunity for Phigenix

The recent success of COVID-19 vaccines marked a triumph for a previously unproven medical technology. The vaccines rely on the genetic instructions known as messenger RNA (mRNA). It prompts cells to make a SARS-CoV-2 protein that trains the immune system to recognize the virus.  Phigenix has designed a Human Beta Defensin-1 (DEFB1) mRNA drug that utilizes a similar nanoparticle system as the COVID-19 vaccine.  Phigenix was the first company to identify DEFB1, which is a component of the innate immune system, as a potent anti-tumor agent.  Phigenix wholly owns this technology and is currently in discussions with a pharmaceutical company to co-develop the world’s first mRNA cancer vaccine that harnesses the patient’s own immune system.